Neuromyelitis Optica: A Case Report
Neuromyelitis optica (NMO, Devic's syndrome) is a demyelinating disease of the central nervous system that predominantly affects the spinal cord and optic nerves. It is often confused with multiple sclerosis. Early discrimination between NMO and multiple sclerosis is important because the two d...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2010-12-01
|
| Series: | Pediatrics and Neonatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957210600678 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850153147900624896 |
|---|---|
| author | Wei-Chia Chia Jian-Nan Wang Ming-Chi Lai |
| author_facet | Wei-Chia Chia Jian-Nan Wang Ming-Chi Lai |
| author_sort | Wei-Chia Chia |
| collection | DOAJ |
| description | Neuromyelitis optica (NMO, Devic's syndrome) is a demyelinating disease of the central nervous system that predominantly affects the spinal cord and optic nerves. It is often confused with multiple sclerosis. Early discrimination between NMO and multiple sclerosis is important because the two diseases have different natural histories and treatment regimens. Seropositivity for NMO-IgG and longitudinally extensive spinal cord lesions (3 or more spinal segments) are characteristic of NMO. Despite the absence of a definitive therapeutic strategy for NMO syndrome, methylprednisolone pulse therapy is recommended in the acute phase. Treatment strategies in relapse phases are aimed at preventing relapses, and increasing evidence shows a better clinical response of immunosuppressive therapy than immuno-modulating therapy (a standard multiple sclerosis-modulating therapy). We describe a 10-year-old girl who had visual loss due to acute optic neuritis at 6 years old and suffered repetitive myelitis 2 years later. NMO was diagnosed because of characteristic longitudinal myelitis and positive NMO-IgG. After combining therapy with prednisolone and an immunosuppressant (cyclophosphamide), the patient's medical condition was stable and no relapse symptoms were observed. |
| format | Article |
| id | doaj-art-130536a8a0074ec6a7eb42704962fbf0 |
| institution | OA Journals |
| issn | 1875-9572 |
| language | English |
| publishDate | 2010-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pediatrics and Neonatology |
| spelling | doaj-art-130536a8a0074ec6a7eb42704962fbf02025-08-20T02:25:48ZengElsevierPediatrics and Neonatology1875-95722010-12-0151634735210.1016/S1875-9572(10)60067-8Neuromyelitis Optica: A Case ReportWei-Chia Chia0Jian-Nan Wang1Ming-Chi Lai2Department of Family Medicine, Chi-Mei Medical Center, Yong Kang Campus, Tainan, TaiwanDepartment of Family Medicine, Chi-Mei Medical Center, Yong Kang Campus, Tainan, TaiwanDepartment of Pediatrics, Chi-Mei Medical Center, Yong Kang Campus, Tainan, TaiwanNeuromyelitis optica (NMO, Devic's syndrome) is a demyelinating disease of the central nervous system that predominantly affects the spinal cord and optic nerves. It is often confused with multiple sclerosis. Early discrimination between NMO and multiple sclerosis is important because the two diseases have different natural histories and treatment regimens. Seropositivity for NMO-IgG and longitudinally extensive spinal cord lesions (3 or more spinal segments) are characteristic of NMO. Despite the absence of a definitive therapeutic strategy for NMO syndrome, methylprednisolone pulse therapy is recommended in the acute phase. Treatment strategies in relapse phases are aimed at preventing relapses, and increasing evidence shows a better clinical response of immunosuppressive therapy than immuno-modulating therapy (a standard multiple sclerosis-modulating therapy). We describe a 10-year-old girl who had visual loss due to acute optic neuritis at 6 years old and suffered repetitive myelitis 2 years later. NMO was diagnosed because of characteristic longitudinal myelitis and positive NMO-IgG. After combining therapy with prednisolone and an immunosuppressant (cyclophosphamide), the patient's medical condition was stable and no relapse symptoms were observed.http://www.sciencedirect.com/science/article/pii/S1875957210600678neuromyelitis opticaneuromyelitis optica-IgGoptic neuritistransverse myelitis |
| spellingShingle | Wei-Chia Chia Jian-Nan Wang Ming-Chi Lai Neuromyelitis Optica: A Case Report Pediatrics and Neonatology neuromyelitis optica neuromyelitis optica-IgG optic neuritis transverse myelitis |
| title | Neuromyelitis Optica: A Case Report |
| title_full | Neuromyelitis Optica: A Case Report |
| title_fullStr | Neuromyelitis Optica: A Case Report |
| title_full_unstemmed | Neuromyelitis Optica: A Case Report |
| title_short | Neuromyelitis Optica: A Case Report |
| title_sort | neuromyelitis optica a case report |
| topic | neuromyelitis optica neuromyelitis optica-IgG optic neuritis transverse myelitis |
| url | http://www.sciencedirect.com/science/article/pii/S1875957210600678 |
| work_keys_str_mv | AT weichiachia neuromyelitisopticaacasereport AT jiannanwang neuromyelitisopticaacasereport AT mingchilai neuromyelitisopticaacasereport |